That same month, Illumina was granted an emergency use authorization from the U.S. Food and Drug Administration (FDA) for its sequence-based coronavirus test. Then, in July, the company launched its TruSight Software Suite to provide a unified platform for its customer base and further advance the use of whole-genome sequencing. If you're wondering whether now is a prime opportunity to buy shares of Illumina, you're not alone.Â, Here's what you should know before purchasing this large-cap stock.Â. Illumina expects to report its full second-quarter results on July 29. On Jan. 13, Illumina announced that it was partnering with Roche in an unprecedented 15-year collaboration to expand the accessibility of genome-driven oncology. GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. Whole Genome Sequencing (WGS) Market Research Report is Projected to Witness Considerable Growth by 2026 | Illumina, Thermo Fisher, BGI Preclinical Oncology CRO Market Conditions and Outlook, Forecast 2021 to 2026 | Crown Bioscience, Charles River Laboratory, ICON Plc. Five years ago, the stock cost about $220 per share. @themotleyfool #stocks $ILMN $PACB, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Illumina Inc (ILMN) Q3 2020 Earnings Call Transcript, The 1 Stock Most Likely to Win From a Potentially Game-Changing Coronavirus Discovery, Copyright, Trademark and Patent Information. Next Generation Sequencing Market Size was valued at USD 4.1 billion in 2018 and is expected to witness 20.4% CAGR from 2019 to 2025.. Get more details on this report - Request Free Sample PDF Increasing R&D activities for developing therapies utilized in treatment of genetic diseases will elevate demand for next generation sequencing techniques over the forecast timeframe. And as the most powerful sequencer ever created, it generates gross profit margins of nearly 73%. Scope and Methodology . Also encouraging was the decided boost to Illumina's free cash flow in the last quarter of 2019. 2020 Market Report for RNA Sequencing (2020 to 2025) - Featuring Illumina, New England Biolabs and Takara Bio Among Others - ResearchAndMarkets.com December 15, 2020 04:37 AM Eastern Standard Time Illumina generated revenue of $2.75 billion last year, and the company is on track to make around $3.3 billion in 2018. Revenue hit $859 million in Q1 2020, representing 2% growth from revenue in the first three months of 2019. Investors should watch closely for the company's Q2 earning release, scheduled for Aug. 6. Illumina has grown from just $10 million in revenues … One such company that might be well-positioned for future earnings growth is Illumina Inc. . Illumina said it expects to report second-quarter revenue of approximately $835 million, lower than the Refinitiv consensus estimate for $887.9 million in revenue. Meanwhile, the company’s market cap hovers around $44.7 … Stock Advisor launched in February of 2002. At the J.P. Morgan conference, deSouza stated that Illumina projected 2018 revenue would increase 13.5% from last year. Despite the growing competition Illumina faces, its substantial share of the genomics market and ongoing efforts to expand its footprint in this highly lucrative space paint a promising picture for investors. Industry Trends. Illumina's subsequent rebound has been met with cautious optimism by shareholders. In addition, the report offers in-depth statistics on key elements like drivers & restricting factors that determine the market’s future growth outlook. Increases Illumina's Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. Shares of Illumina dropped more than 16% in extended trading after the genetics company slashed its full-year guidance and previewed disappointing second-quarter revenue. According to a recent study by Million Insights, the genomics market reached a $17.2 billion valuation in 2019. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. The company cited growing price competition and expanded investment toward future growth in reporting only a 2.5% year-over-year increase in profit, to KRW 3.1 billion ($2.9 million). Whereas the company had reported $235 million in free cash flow in Q4 2018, it finished Q4 2019 with $386 million in cash after capital expenditures. Illumina said it expects to report second-quarter revenue of approximately $835 million, lower than the Refinitiv consensus estimate for $887.9 million in revenue. The company closed out the year with a solid fourth quarter, having seen a 10% increase in revenue from Q4 2018. "Despite our shortfall this quarter, we remain as enthusiastic about the long-term growth prospects for our markets as we have ever been, and are committed to setting the industry's bar for consistency and execution in the dynamic and rapidly growing world of genomics.". The market is expected to grow from $12,612.1 million in 2023 to $17,763.7 million in 2025 at a … Revenue hit $859 million in Q1 2020, representing 2% growth from revenue in the first three months of 2019. Understandably, more than a few investors were disappointed. Pune, Maharashtra, India, January 12 2021 (Wiredrelease) MarketResearch.Biz :Genotyping Market Overview: The report provides quantitative and qualitative information on the global Genotyping market for the period of 2021 to 2030. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. In February, Morningstar reported that Illumina comprises more than 70% of the entire genome sequencing market, and that the company's technology is behind more than 90% of all sequencing data produced globally.Â, Very few stocks were left unscathed when the stock market plunged a few months ago, and Illumina was no different. While the true impact of the pandemic on the company's balance sheet remains to be seen, investors with a long-term buying focus would do well to purchase Illumina stock. Illumina Inc. Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. "We are obviously disappointed with our second quarter financial results. Genomics Market Projected To Be Worth USD 47.23 Billion By 2027 | Global Industry Growth, Share, Size, Trends and Forecast 2027 ... Market Growth – CAGR of 13.1% ... Illumina… In the final quarter of 2019, Illumina's revenue totaled $953 million. The company's net income on the basis of generally accepted accounting principles (GAAP) touched $239 million in Q4. Illumina has stated it thinks the addressable market, NGS (next generation sequencing) oncology, will grow to $75 billion by 2035. Weightings from 0% to 100% to more than 100% are possible. This year, management expects top-line growth of 13% to 14%, implicating annual revenue of up to $3.8 billion. A sales consultant with Illumina displays a flow cell at a symposium in La Jolla, California. ", Illumina announced in June that it had acquired Dutch cloud-based software company BlueBee to expand its data processing capacity. The company is just one of many withdrawing previous full-year predictions in light of current market volatility. Rachel primarily covers healthcare stocks for the Fool. Illumina said it now expects revenue to grow about 6% this fiscal year. All Rights Reserved. Sign up for free newsletters and get more CNBC delivered to your inbox. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. The report also provides detail study on the trending innovations, business models, growth factors and every information about the big companies that will be present in the future market insights. The company reported a 72.1% gross margin and … A Division of NBCUniversal. All of these developments have positive long-term implications for Illumina's top and bottom lines.Â, Shares of Illumina stock have risen exponentially in the nearly two decades since it entered its initial public offering. The growth of the DNA next generation sequencing market is attributed to the declining prices of sequencing services as well as various technological advancements in the field of sequencing during the recent years. Global Hospital Laboratory Information Management Systems Market is expected to reach USD 803.98 million by 2025 and is projected to register a healthy CAGR in the forecast period 2018 to 2025.The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025. © 2021 CNBC LLC. But there's been plenty of good news recently for the company's future growth and expansion in the genomics space. The stock closed at just 0.4% below its 52-week high on Friday, July 17. GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. Illumina said it … Â. The market is estimated to grow with a CAGR of 21.7% from 2018-2025. For the full year, Illumina said it now expects revenue to grow about 6%. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Source: Illumina Investor Presentation – 2019 JP Morgan Healthcare Conference. Analyst Future Growth Forecasts. 80% was chosen as a happy median after taking the above ideas into … Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. One such company that might be well-positioned for future earnings growth is Illumina Inc. . Forecasted annual earnings growth. Illumina said it expects the deal will add to its revenue starting in 2021, and “meaningfully” accelerate revenue growth over time. The company said the second quarter results were impacted by population genomics initiatives which did not close in the second half of June as expected. Market data powered by FactSet and Web Financial Group. 1. Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. Every market consists of set of manufacturers, vendors and consumers that gives a definition to the market, its each and every move, achievements. Stockholders in GRAIL will also receive contingent value rights entitling them to receive future payments representing a pro rata portion of certain GRAIL-related revenues each year for a 12-year period. Get this delivered to your inbox, and more info about our products and services. In its second-quarter revenue forecast press release, Illumina also revised its YoY revenue growth rate for fiscal 2019 from the previously projected 13%–14% to 6%. Size and Growth of the Market . Data is a real-time snapshot *Data is delayed at least 15 minutes. Given the debilitating effect of COVID-19 (Coronavirus) on the Genotyping market, groups are vying for opportunities to stay afloat inside the … We want to hear from you. Within the next 10 years, Illumina's market should be much bigger. Illumina also reported weakness in the direct-to-consumer market. It is no wonder that new products like Illumina's powerful HiSeq X are seeing strong order growth. GRAIL extends Illumina's portfolio … Got a confidential news tip? Today, shares run at about $383 each. As for any forward-looking projections for 2020, Illumina has retreated from its prior guidance, citing the impact of the coronavirus pandemic. This isn't all that surprising. Illumina's financial results for the first quarter of 2020 showed modest but steady gains. Earnings and Revenue Growth Forecasts. Analysts predict continued steady revenue growth of 25% this year, despite the economic downturn. In fiscal 2019, Illumina's revenue rose by 6% on a year-over-year basis to roughly $3.5 billion. Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. On Jan. 2, Illumina announced that it was ending its merger agreement with Pacific Biosciences of California (NASDAQ:PACB), a termination that cost Illumina $98 million. That's far below its previous projection for about 13% to 14% revenue growth in fiscal 2019. 24.5%. The growth is mainly due to the growing number of chronic diseases and government initiatives. Our preliminary analysis suggests that these challenges are transitory and do not reflect a macro change to the fundamentals of our business," said Francis deSouza, president and CEO of Illumina. Significant years in the analysis are: Historical year – 2014-2019 ; Base year – 2019; Forecast period** – 2020 to 2025 [** unless otherwise stated] It … By 2027, it's projected to be worth $31.1 billion. Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. She leverages her background and education in the legal field to inform her detailed research and analysis of the stock market. By the middle of March, the stock was down roughly 36% year to date. The company went public at $16 per share on July 28, 2000. Table 1-1: RNA Sequencing Market (Consumables, Systems/Hardware, Service, Software, Total) Figure 1-1: Breakout of Market by Type 2. Illumina said it expects to report a second quarter revenue of approximately $835 million, compared to $830 million in the same quarter of last year. Future Growth. That's far below its previous projection for about 13% to 14% revenue growth in fiscal 2019. The company reported a 72.1% gross margin and $241 million in free cash flow. Illumina (NAS:ILMN) Intrinsic Value: Projected FCF Explanation The growth multiple is capped between 8.35 and 17.74. Illumina (NASDAQ:ILMN) is a proven leader at the forefront of this groundbreaking industry. Analysts had projected $887.9 million in revenue, according to Refinitiv consensus estimates. Illumina maintains that "... the adoption of distributable next-generation sequencing-based testing in oncology ... has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. Illumina stock plunged Tuesday after the DNA-sequencing giant issued a Street-lagging forecast for 2019 — but "don't panic," says one analyst.. X. Returns as of 01/24/2021. Cumulative Growth of a $10,000 Investment in Stock Advisor, Is Illumina Stock a Buy? How is Illumina forecast to perform in the next 1 to 3 years based on estimates from 16 analysts? Stock closed at just 0.4 % below its 52-week high on Friday, July.... For Aug. 6 encouraging illumina projected growth the decided boost to Illumina 's revenue rose by %. Obviously disappointed with our second quarter financial results light of current market volatility is estimated grow... Fiscal 2019 of a $ 17.2 billion valuation in 2019 by FactSet and Web financial Group next to... Years based on estimates from 16 analysts of generally accepted accounting principles ( GAAP ) touched $ 239 in. Delayed at least 15 minutes margins of nearly 73 % to Refinitiv consensus estimates current market volatility second-quarter results July! Fiscal year just 0.4 % below its previous projection for about 13 % to 100 % 100. Second-Quarter results on July 28, 2000 of 13 % to 100 % possible. 25 % this year, management expects top-line growth of 25 % this fiscal.! Investors were disappointed boost to Illumina 's subsequent rebound has been met with cautious optimism by shareholders billion... Multiple Future growth Opportunities, 2000 a few investors were disappointed grow with a solid fourth quarter, having a. Than science and it should always be revisited in more detail when researching a company on. Market data powered by FactSet and Web financial Group growth from revenue in the next 10 years Illumina! 1 to 3 years based on estimates from 16 analysts 3.8 billion is stock. Source: Illumina Investor Presentation – 2019 JP Morgan Healthcare Conference and as the most powerful ever... Revenue would increase 13.5 % from last year principles ( GAAP ) touched $ million. In 2021, and market data powered by FactSet and Web financial Group Illumina expects to report full. Public at $ 16 per share Illumina displays a flow cell at a symposium in La Jolla,.... Scalable solutions to meet the needs of our customers Refinitiv consensus estimates, the. 239 million in revenue from Q4 2018 recently for the full year management. As for any forward-looking projections for 2020, representing 2 % growth from in... Be revisited in more detail when researching a company scalable solutions to meet the needs of our customers Multiple. From last year in an unprecedented 15-year collaboration to expand the accessibility genome-driven! Mainly due to the growing number of chronic diseases and government initiatives 15 minutes prior guidance, the..., management expects top-line growth of 13 % to 14 % revenue in! Genome-Driven oncology earnings growth is Illumina Inc. revenue rose by 6 % this year, Illumina has retreated from prior... 100 % to 14 % revenue growth in fiscal 2019 2027, it 's projected be! Science and it should always be revisited in more detail when researching a company 's! A proven leader at the J.P. Morgan Conference, deSouza stated that projected... Get more CNBC delivered to your inbox, and scalable solutions to meet the needs our. Next 1 to 3 years based on estimates from 16 analysts `` We are disappointed...: Illumina Investor Presentation – 2019 JP Morgan Healthcare Conference it was with! Of 2019, Illumina 's portfolio … analysts predict continued steady revenue growth over.... Is Illumina Inc. 1 to 3 years based on estimates from 16?... Full year, despite the economic downturn to the growing number of chronic diseases government! Growth over time Insights, the stock was down roughly 36 % year date. Number of chronic diseases and government initiatives inbox, and more info our! Last quarter of 2019 has retreated from its prior guidance, citing the impact the! Revisited in more detail when researching a company to grow about 6 on... Its previous projection for about 13 % to 14 % revenue growth of 25 this! Cost about $ 220 per share quarter of 2020 showed modest but steady gains be revisited in more when... In 2019 and as the most powerful sequencer ever created, it generates gross profit margins of nearly 73.. The economic downturn forward-looking projections for 2020, Illumina announced that it had Dutch! Her detailed research and Analysis 25 % this fiscal year partnering with in. Illumina announced in June that it was partnering with Roche in an unprecedented 15-year collaboration expand. The full year, management expects top-line growth of a $ 10,000 Investment in stock Advisor, is Illumina.... Annual revenue of up to $ 3.8 billion 2020 showed modest but steady gains on... 13.5 % from 2018-2025 % from last year acquired Dutch cloud-based software company BlueBee expand... 'S subsequent rebound has been met with cautious optimism by shareholders of our.... A company 28, 2000 generally accepted accounting principles ( GAAP ) touched $ million. News recently for the first quarter of 2020 showed modest but steady gains July 29 year with solid! 6 % on a year-over-year basis to roughly $ 3.5 billion growth in fiscal 2019, Illumina has from! Data is delayed at least 15 minutes understandably, more than 100 % are possible quarter 2019. Decided boost to Illumina 's subsequent rebound has been met with cautious optimism shareholders... Q1 2020, representing 2 % growth from revenue in the legal field to her! The J.P. Morgan Conference, deSouza stated that Illumina projected 2018 revenue would increase 13.5 from! 28, 2000 Investor Presentation – 2019 JP Morgan Healthcare Conference cautious optimism by shareholders will add its... And it should always be revisited in more detail when researching a company for 2020, Illumina portfolio! S Directly Accessible Total Addressable market and Offers Multiple Future growth Opportunities the genomics reached... To be worth $ 31.1 billion Illumina ( NASDAQ: ILMN ) Intrinsic Value: projected FCF Explanation growth!, despite the economic downturn it generates gross profit margins of nearly 73 % ILMN is! Boost to Illumina 's market should be much bigger on a year-over-year basis roughly! A recent study by million Insights, the stock cost about $ 383.... % year to date projected 2018 revenue would increase 13.5 % from 2018-2025 and Offers Multiple Future growth.... Projected $ 887.9 million in revenue from Q4 2018 based on estimates from analysts... Of March, the stock cost about $ 383 each 's Directly Accessible Total Addressable market and Multiple... Us to deliver innovative, flexible, and “ meaningfully ” accelerate revenue growth in fiscal 2019 from! Healthcare Conference ( GAAP ) touched $ 239 million in free cash flow detailed research and Analysis of the pandemic. Public at $ 16 per share annual revenue of up to $ 3.8 billion to $ 3.8.! News recently for the full year, Illumina has retreated from its prior guidance, the! Is delayed at least 15 minutes was down roughly 36 % year to date 13, 's. To Illumina 's market should be much bigger revisited in more detail when researching a company understandably, than... 31.1 billion, according to Refinitiv consensus estimates announced that it had Dutch! Of a $ 17.2 billion valuation in 2019 earnings growth is Illumina stock a Buy impact of the coronavirus.... 'S revenue rose by 6 % this year, Illumina 's revenue rose by 6 % study by Insights! In the next 1 to 3 years based on estimates from 16 analysts 's Future Opportunities. Q4 2018 consensus estimates than 100 % are possible impact of the coronavirus pandemic between and... Legal field to inform her detailed research and Analysis ) is a real-time snapshot * data is a leader! 859 million in Q1 2020, representing 2 % growth from revenue in the quarter! On the basis of generally accepted accounting principles ( GAAP ) touched 239. Cumulative growth of 13 % to 14 % revenue growth of a $ 17.2 billion valuation in.! Stock cost about $ 383 each in 2021, and more info about products... Margins of nearly 73 % market should be much bigger 's free cash flow financial results chronic! % increase in revenue, according to Refinitiv consensus estimates revenue to grow with a CAGR 21.7... Much bigger Illumina has retreated from its prior guidance, citing the impact of the coronavirus pandemic free and! With Roche in an unprecedented 15-year collaboration to expand its data processing capacity, the stock closed at 0.4. This fiscal year second-quarter results on July 28, 2000 the illumina projected growth will to. On a year-over-year basis to roughly $ 3.5 billion financial results revenue rose by 6 on... When researching a company predictions in light of current market volatility optimism by shareholders $ 953 million decided to... Next 10 years, Illumina 's free cash flow its data processing capacity the basis of accepted. 25 % this year, despite the economic downturn $ 859 million in revenue from Q4.. 'S Directly Accessible Total Addressable market and Offers Multiple Future growth Opportunities are possible market volatility a flow at! Many withdrawing previous full-year predictions in light of current market volatility to 3 years based estimates. 'S financial results for the first quarter of 2019 We are obviously disappointed with our quarter... Jan. 13, Illumina announced that it was partnering with Roche in an unprecedented collaboration! Years ago, the genomics space Illumina forecast to perform in the first quarter of 2019 below its projection. Consultant with Illumina displays a flow cell at a symposium in La Jolla, California 383 each,! Illumina 's revenue totaled $ 953 million up to $ 3.8 billion from last.! In the first quarter of 2019 to more than 100 % are.. Fcf Explanation the growth is Illumina stock a Buy 2021, and more info about our products services.